Xeris Biopharma Holdings annual r&d spending
2020
2021
2022
2023
2024
2025
Xeris Biopharma Holdings R&D Spending Growth & History (XERS)
Xeris Biopharma Holdings's r&d spending was $31.2M for fiscal 2025.
View full Xeris Biopharma Holdings company overviewXeris Biopharma Holdings annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $31.2M | $5.6M | +21.93% |
| 2024 | 2024-12-31 | $25.6M | $3.2M | +14.41% |
| 2023 | 2023-12-31 | $22.3M | $1.4M | +6.56% |
| 2022 | 2022-12-31 | $21.0M | −$4.2M | −16.67% |
| 2021 | 2021-12-31 | $25.2M | $4.2M | +20.26% |
| 2020 | 2020-12-31 | $20.9M | — | — |
Xeris Biopharma Holdings quarterly r&d spending
Q3.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q2.23
Q3.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $10.7M | $2.6M | +32.45% |
| Q1 2026 | 2026-03-31 | $8.8M | $1.0M | +13.29% |
| Q4 2025 | 2025-12-31 | $7.9M | $1.8M | +29.25% |
| Q3 2025 | 2025-09-30 | $7.5M | $1.6M | +27.09% |
| Q2 2025 | 2025-06-30 | $8.1M | $2.3M | +39.87% |
| Q1 2025 | 2025-03-31 | $7.8M | −$68,000 | −0.87% |
| Q4 2024 | 2024-12-31 | $6.1M | — | — |
| Q3 2024 | 2024-09-30 | $5.9M | $854,000 | +16.96% |
| Q2 2024 | 2024-06-30 | $5.8M | −$328,000 | −5.39% |
| Q1 2024 | 2024-03-31 | $7.8M | — | — |
| Q3 2023 | 2023-09-30 | $5.0M | −$1.0M | −16.70% |
| Q2 2023 | 2023-06-30 | $6.1M | $2.4M | +63.72% |
| Q4 2022 | 2022-12-31 | $5.0M | −$5.1M | −50.85% |
| Q3 2022 | 2022-09-30 | $6.0M | $380,000 | +6.71% |
| Q2 2022 | 2022-06-30 | $3.7M | −$1.7M | −30.93% |
| Q1 2022 | 2022-03-31 | $6.3M | $2.2M | +55.01% |
| Q4 2021 | 2021-12-31 | $10.1M | — | — |
| Q3 2021 | 2021-09-30 | $5.7M | $1.8M | +46.10% |
| Q2 2021 | 2021-06-30 | $5.4M | — | — |
| Q1 2021 | 2021-03-31 | $4.0M | — | — |
| Q3 2020 | 2020-09-30 | $3.9M | — | — |
Xeris Biopharma Holdings r&d spending trends
Over the last five fiscal years, Xeris Biopharma Holdings's r&d spending increased from $20.9M to $31.2M, a change of $10.2M. The latest reported quarter, Q2 2026, shows $10.7M.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Xeris Biopharma Holdings source filings ↗